Loading organizations...
§ Private Profile · Noida, Uttar Pradesh, India
Vgenomics - Your DNA Decoder is a company.
Vgenomics offers an AI-powered platform for rare disease diagnosis and therapeutic target discovery. It integrates artificial intelligence with multi-omics data, translating biological information into actionable clinical insights. Key products include VGen23, a genomic analysis solution for clinical labs and pharma research, and RDx, an AI-driven platform aiding healthcare providers in diagnostic decisions.
Founded by Dr. Rahila Sardar, Vgenomics addresses the unmet medical needs of individuals with genetic conditions. Dr. Sardar's insight focused on shortening diagnostic and therapeutic odysseys experienced by rare disease patients. This vision drove the company to build advanced genomic and AI solutions, accelerating understanding and treatment.
Vgenomics serves clinical diagnostic laboratories, pharmaceutical companies, and healthcare providers. The company envisions universal access to timely diagnosis and effective treatments, improving outcomes for rare disease patients. Integrating clinical AI, multi-omics analytics, and collaborative research, Vgenomics advances precision medicine, ensuring breakthroughs directly benefit those in need.
Key people at Vgenomics - Your DNA Decoder.
Vgenomics - Your DNA Decoder was founded in 2022 by Sameer Malik (Co-Founder).
Key people at Vgenomics - Your DNA Decoder.
Vgenomics is a Noida-based health tech startup founded in 2021 that develops AI-powered genomic analysis solutions for diagnosing and treating rare genetic diseases.[3][1] Its flagship product, RgenX, is a cloud platform offering tools like RgenX-DM for clinical diagnostics in labs, RgenX-LENS for disease insights and novel drug target discovery for pharma companies, and an AI-driven rare disease diagnosis platform that aids healthcare providers.[1][4] The company targets the unmet needs of 350 million rare disease patients worldwide—70% children across 7,000+ diseases, where only 5% have FDA-approved treatments—by accelerating diagnostics, reclassifying Variants of Uncertain Significance (VUS), and enabling personalized care through genetic testing and counseling.[1][5] Serving labs, pharmaceutical firms, and healthcare providers, Vgenomics solves the "diagnostic odyssey" with faster, AI-enhanced analysis of genomic data.[1][2]
Vgenomics emerged in 2021 from Noida, India, amid a push for biotech innovations in genomic sequencing and analysis.[3] The founding team, led by scientific expertise from Dr. Rahila and combining over 40 years in genomics, molecular biology, and computational science, aimed to tackle the diagnostic challenges of rare diseases.[2] The idea stemmed from merging AI with genomic data to unlock early diagnosis and tailored treatments, addressing the global burden where millions face prolonged uncertainty.[1][2] Early traction focused on building RgenX as a comprehensive solution, evolving from initial sequencing services to a dynamic, self-updating platform for VUS interpretation and drug discovery.[1][3]
Vgenomics rides the AI-biotech convergence trend, where genomic sequencing costs plummet and AI deciphers vast datasets to personalize medicine—critical for rare diseases lacking 95% of treatments.[1] Timing aligns with global pushes for precision health, as 350 million patients (mostly children) demand faster solutions amid rising genomic data volumes.[1] Market forces like expanding pharma R&D for orphan drugs and India's biotech boom favor it, positioning Vgenomics to influence ecosystems by equipping labs/pharma with scalable tools and accelerating therapeutic breakthroughs.[1][3][4]
Vgenomics is poised to scale RgenX globally, potentially partnering with more pharma giants for drug discovery amid AI's genomics revolution.[1][4] Trends like multimodal AI (integrating genomics with multi-omics) and regulatory nods for AI diagnostics will propel growth, evolving its role from diagnostics to full therapeutic pipelines. As rare disease awareness surges, Vgenomics could redefine access to hope for millions, turning genomic "blueprints" into actionable care—one genome at a time.[1][2]
